Evidence map›Paper›PMID 33762014›Full record

ReviewStem cell research & therapy2021

Advances in intranasal application of stem cells in the treatment of central nervous system diseases.

Yu-Ting Zhang, Kai-Jie He, Jin-Bao Zhang, Quan-Hong Ma, Fen Wang, Chun-Feng Liu

Open access · goldAbstract readReview
In one paragraph

Review in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. The Therapeutic Potential of Stem Cells in Depression.International journal of molecular sciences · 2025
    Review
  16. Review
  17. Review
  18. Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yu-Ting Zhang *Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Kai-Jie He *Institute of Neuroscience, Soochow University, Suzhou, 215123, China.
Jin-Bao ZhangDepartment of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Quan-Hong MaInstitute of Neuroscience, Soochow University, Suzhou, 215123, China.
Fen WangInstitute of Neuroscience, Soochow University, Suzhou, 215123, China. wangfen_1982@126.com.
Chun-Feng LiuDepartment of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China. liuchunfeng@suda.edu.cn.ORCID 0000-0002-8364-0219
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cells are characterized by their self-renewal and multipotency and have great potential in the therapy of various disorders. However, the blood-brain barrier (BBB) limits the application of stem cells in the therapy of neurological disorders, especially in a noninvasive way. It has been shown that small molecular substances, macromolecular proteins, and even stem cells can bypass the BBB and reach the brain parenchyma following intranasal administration. Here, we review the possible brain-entry routes of transnasal treatment, the cell types, and diseases involved in intranasal stem cell therapy, and discuss its advantages and disadvantages in the treatment of central nervous system diseases, to provide a reference for the application of intranasal stem cell therapy.

Indexed as

Central Nervous System DiseasesAdministration, IntranasalBlood-Brain BarrierBrainDrug Delivery SystemsHumansStem CellsCentral nervous systemIntranasal applicationStem cells

Identifiers

PMID33762014
PMCPMC7992869
OpenAlexW3138405253

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.